Skip to main content
padlock icon - secure page this page is secure

Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer‐associated venous thromboembolism

Buy Article:

$59.00 + tax (Refund Policy)

Low molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cancer; enoxaparin; low molecular weight heparin; rivaroxaban; venous thromboembolism

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more